The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenues from external customers | 83,043 | - |
| Personnel costs | 52,863 | - |
| Organizational and marketing costs | 39,983 | - |
| Inventory usage | 6,127 | - |
| Clinical studies and publication costs | 2,183 | - |
| Professional services | 2,524 | - |
| Other segment items | 8,580 | - |
| Net (loss) income | -501 | -21,325 |
| Depreciation and amortization | 3,816 | 33,178 |
| Stock-based compensation expense | 12,100 | 22,387 |
| Change in fair value of equity securities | 3,561 | -240 |
| Deferred income taxes | 116 | -5,437 |
| Accretion of discounts on marketable investment securities | 905 | 2,606 |
| Other | -63 | -219 |
| Accounts receivable | -1,911 | 1,307 |
| Prepaid expenses and other current assets | -161 | 4,696 |
| Inventory | 307 | 231 |
| Operating lease assets | -352 | -664 |
| Other assets | 41 | 13 |
| Accounts payable | 1,406 | 1,689 |
| Operating lease liabilities | -197 | -869 |
| Accrued compensation | 6,790 | -7,582 |
| Other accrued and current liabilities | 1,428 | 474 |
| Net cash provided by operating activities | 22,631 | 14,785 |
| Purchases of marketable investment securities | 58,474 | 92,832 |
| Proceeds from maturities of marketable investment securities | 54,900 | 80,300 |
| Purchases of debt securities classified as held-to-maturity | 0 | 5,569 |
| Asset acquisition, net of cash and cash equivalents acquired | 0 | 18,726 |
| Purchases of property and equipment | 14,834 | 14,003 |
| Proceeds from sale of property and equipment | 19 | 21 |
| Net cash used in investing activities | -18,389 | -50,809 |
| Proceeds from exercise of common stock options | 77 | 37 |
| Payment of employees taxes on vested restricted stock units | 1,185 | 3,104 |
| Proceeds from contributions to the employee stock purchase plan | 220 | 1,482 |
| Repayment of principal portion of finance lease liabilities | 31 | 57 |
| Proceeds from lease incentives received | 0 | 190 |
| Proceeds from issuance of term debt | 0 | 0 |
| Net cash (used in) provided by financing activities | -919 | -1,452 |
| Net change in cash and cash equivalents | 3,323 | -37,476 |
| Cash and cash equivalents at beginning of period | 119,709 | - |
| Cash and cash equivalents at end of period | 85,556 | - |
CASTLE BIOSCIENCES INC (CSTL)
CASTLE BIOSCIENCES INC (CSTL)